T(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs

Blood Cancer Journal

Volumn 5, Issue 2, 2015, Pages

  Narita, T ^a   Inagaki, A ^b   Kobayashi, T ^c   Kuroda, Y ^d   Fukushima, T ^e   Nezu, M ^f   Fuchida, S ^g   Sakai, H ^h   Sekiguchi, N ⁱ   Sugiura, I ^j   Maeda, Y ^k   Takamatsu, H ^l   Tsukamoto, N ^m   Maruyama, D ⁿ   Kubota, Y ^o   Kojima, M ^p   Sunami, K ^q   Ono, T ^r   Ri, M ^a   Tobinai, K ⁿ   Iida, S ^a   more..

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Nagoya City University West Medical Center   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e KANAZAWA MEDICAL UNIVERSITY   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^g National Hospital Organization   (Japan)

^h ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION DISASTER MEDICAL CENTER   (Japan)

^j TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^k OKAYAMA UNIVERSITY   (Japan)

^l KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^m GUNMA UNIVERSITY HOSPITAL   (Japan)

ⁿ NATIONAL CANCER CENTER HOSPITAL   (Japan)

^o SAGA UNIVERSITY   (Japan)

^p TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^r HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD56 ANTIGEN; CCND1 PROTEIN, HUMAN; CYCLIN D1; NCAM1 PROTEIN, HUMAN; TUMOR PROTEIN;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; KARYOTYPING; LETTER; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; ADULT; AGED; BIOSYNTHESIS; CHROMOSOME 14; CHROMOSOME 16; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 16; CYCLIN D1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84927939137     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2015.6     Document Type: Letter

References (15)

1. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Intergroupe Francophone du Myélome. Blood 2002; 100: 1579-1583.
2. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837-2840.
3. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28: 4630-4634.
4. Chang H, Qi Q, Xu W, Patterson B. c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma. Leukemia 2007; 21: 1572-1574.
5. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575.
6. Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011; 117: 2009-2011.
7. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
8. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
9. Tajima E, Uranishi M, Iida S, Komatsu H, Nitta M, Ueda R. Global real-time quantification/reverse transcription-polymerase chain reaction for detecting proto-oncogenes associated with 14q32 chromosomal translocation in multiple myeloma. Haematologica 2005; 90: 559-562.
10. Inagaki A, Tajima E, Uranishi M, Totani H, Asao Y, Ogura H et al. Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma. Leuk Res 2013; 37: 1648-1655.
11. Yeung J, Chang H. Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J Clin Pathol 2008; 61: 832-836.
12. An G, Xu Y, Shi L, Zou D, Deng S, Sui W et al. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leuk Res 2013; 37: 1251-1257.
13. Eychène A, Rocques N, Pouponnot C. A new MAFia in cancer. Nat Rev Cancer. 2008; 8: 683-693.
14. Herath NI, Rocques N, Garancher A, Eychène A, Pouponnot C. GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer J 2014; 4: e175.
15. Reddy MV, Akula B, Cosenza SC, Athuluridivakar S, Mallireddigari MR, Pallela VR et al. Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7, 8-dihydro-pyrido[2, 3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). J Med Chem 2014; 57: 578-599.